A policyowner whose permanent life policy was issued five years ago at the Preferred non-tobacco class applies for a reduction in cost-of-insurance through the insurer's re-underwriting (reconsideration) program. Updated labs show a borderline HbA1c and a slightly elevated blood pressure on new medication. Under industry practice, what is the MOST likely outcome the insurer offers?
